Site and timing of recurrence in postoperative serum mutant K-ras positive patients
| Patient | Dukes’ stage | Time of positive serum k-ras* | Time of recurrence† | Site of recurrence | Lead time‡ |
|---|---|---|---|---|---|
| All time periods are in months. | |||||
| *This is the postoperative duration when a positive serum mutant KRAS2 test was first detected. | |||||
| †The postoperative duration when clinical recurrence was first detected. | |||||
| ‡Lead time is the duration by which serum mutant KRAS2 positivity pre-dated the development of clinical recurrence. | |||||
| ¶Patient M39 developed a local recurrence and became serum mutant KRAS2 negative following resection of the recurrence. | |||||
| §These patients were concomitantly carcinoembryonic antigen and serum mutant KRAS2 positive. | |||||
| C12 | D | 5 | 21 | Retroperitoneum | 16 |
| C31 | B | 3 | 8 | Liver | 5 |
| M39¶ | B | 15 | 18 | Colon | 3 |
| M9 | C | 16 | 20 | Liver | 4 |
| M10 | C | 20 | 28 | Pelvis | 8 |
| M12 | C | 19 | 23 | Bladder | 4 |
| M22 | B | 26 | 32 | Lung | 6 |
| M65 | C | 36 | 36§ | Liver | 0 |
| M55 | B | 20 | 20§ | Liver | 0 |
| M57 | B | 24 | 24§ | Lung | 0 |
| C28 | B | 14 | None @ 26 | — | — |
| C52 | A | 12 | None @ 24 | — | — |
| C64 | B | 8 | None @ 19 | — | — |
| C67 | B | 7 | None @ 18 | — | — |
| M32 | C | 46 | None @ 58 | — | — |
| M6 | B | 24 | None @ 36 | — | — |